Cyclosporine A and Mycophenolate Mofetil vs Cyclosporine A and Methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings

Frank Neumann(Beth Israel Deaconess Medical Center), Guido Kobbe(Düsseldorf University Hospital), Christoph Tapprich(Johnson & Johnson (Germany)), Thorsten Graef(Beth Israel Deaconess Medical Center), Rainer Haas(Beth Israel Deaconess Medical Center), Matthias Vaupel(Heinrich Heine University Düsseldorf), Axel Hinke, Roland Fenk(Beth Israel Deaconess Medical Center), Ulrich Germing(Heinrich Heine University Düsseldorf), Ulrich Steidl(Heinrich Heine University Düsseldorf)
Bone Marrow Transplantation
April 11, 2005
10.1038/sj.bmt.1704956
Cited by 81

Related Papers

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
|The Lancet|2013|1.5k
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
|Journal of Clinical Oncology|2009|963
Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
|New England Journal of Medicine|2015|937
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
|European Journal of Cancer|2011|615
Differential impact of allelic ratio and insertion site in FLT3-ITD–positive AML with respect to allogeneic transplantation
|Blood|2014|400